ID   B3GA3_HUMAN             Reviewed;         335 AA.
AC   O94766; B7ZAB3; Q96I06; Q9UEP0;
DT   01-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   26-APR-2004, sequence version 2.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3;
DE            EC=2.4.1.135 {ECO:0000269|PubMed:25893793};
DE   AltName: Full=Beta-1,3-glucuronyltransferase 3;
DE   AltName: Full=Glucuronosyltransferase I;
DE            Short=GlcAT-I;
DE   AltName: Full=UDP-GlcUA:Gal beta-1,3-Gal-R glucuronyltransferase;
DE            Short=GlcUAT-I;
GN   Name=B3GAT3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RC   TISSUE=Placenta;
RX   PubMed=9506957; DOI=10.1074/jbc.273.12.6615;
RA   Kitagawa H., Tone Y., Tamura J., Neumann K.W., Ogawa T., Oka S.,
RA   Kawasaki T., Sugahara K.;
RT   "Molecular cloning and expression of glucuronyltransferase I involved
RT   in the biosynthesis of the glycosaminoglycan-protein linkage region of
RT   proteoglycans.";
RL   J. Biol. Chem. 273:6615-6618(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CHARACTERIZATION, AND
RP   MUTAGENESIS.
RX   PubMed=10842173; DOI=10.1074/jbc.M002182200;
RA   Ouzzine M., Gulberti S., Netter P., Magdalou J., Fournel-Gigleux S.;
RT   "Structure/function of the human Ga1beta1,3-glucuronosyltransferase.
RT   Dimerization and functional activity are mediated by two crucial
RT   cysteine residues.";
RL   J. Biol. Chem. 275:28254-28260(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-335 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9927678; DOI=10.1073/pnas.96.3.974;
RA   Herman T., Horvitz H.R.;
RT   "Three proteins involved in Caenorhabditis elegans vulval invagination
RT   are similar to components of a glycosylation pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:974-979(1999).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=10526176; DOI=10.1016/S0014-5793(99)01287-9;
RA   Tone Y., Kitagawa H., Imiya K., Oka S., Kawasaki T., Sugahara K.;
RT   "Characterization of recombinant human glucuronyltransferase I
RT   involved in the biosynthesis of the glycosaminoglycan-protein linkage
RT   region of proteoglycans.";
RL   FEBS Lett. 459:415-420(1999).
RN   [8]
RP   SUBCELLULAR LOCATION, VARIANT JDSCD GLN-277, CHARACTERIZATION OF
RP   VARIANT JDSCD GLN-277, AND INVOLVEMENT IN JDSCD.
RX   PubMed=21763480; DOI=10.1016/j.ajhg.2011.05.021;
RA   Baasanjav S., Al-Gazali L., Hashiguchi T., Mizumoto S., Fischer B.,
RA   Horn D., Seelow D., Ali B.R., Aziz S.A., Langer R., Saleh A.A.,
RA   Becker C., Nurnberg G., Cantagrel V., Gleeson J.G., Gomez D.,
RA   Michel J.B., Stricker S., Lindner T.H., Nurnberg P., Sugahara K.,
RA   Mundlos S., Hoffmann K.;
RT   "Faulty initiation of proteoglycan synthesis causes cardiac and joint
RT   defects.";
RL   Am. J. Hum. Genet. 89:15-27(2011).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   FUNCTION, INTERACTION WITH PXYLP1, AND MUTAGENESIS OF GLU-281.
RX   PubMed=24425863; DOI=10.1074/jbc.M113.520536;
RA   Koike T., Izumikawa T., Sato B., Kitagawa H.;
RT   "Identification of phosphatase that dephosphorylates xylose in the
RT   glycosaminoglycan-protein linkage region of proteoglycans.";
RL   J. Biol. Chem. 289:6695-6708(2014).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 76-335 IN COMPLEX WITH
RP   UDP-GLUCURONIC ACID AND GALACTOSE MOIETY OF SUBSTRATE GLYCOPROTEIN.
RC   TISSUE=Liver;
RX   PubMed=10946001; DOI=10.1074/jbc.M007399200;
RA   Pedersen L.C., Tsuchida K., Kitagawa H., Sugahara K., Darden T.A.,
RA   Negishi M.;
RT   "Heparan/chondroitin sulfate biosynthesis. Structure and mechanism of
RT   human glucuronyltransferase I.";
RL   J. Biol. Chem. 275:34580-34585(2000).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 76-335 IN COMPLEX WITH
RP   UDP-GLUCURONIC ACID, AND ACTIVE SITE.
RX   PubMed=11950836; DOI=10.1074/jbc.M112343200;
RA   Pedersen L.C., Darden T.A., Negishi M.;
RT   "Crystal structure of beta 1,3-glucuronyltransferase I in complex with
RT   active donor substrate UDP-GlcUA.";
RL   J. Biol. Chem. 277:21869-21873(2002).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 76-335 IN COMPLEX WITH
RP   URIDINE-5'-DIPHOSPHATE AND GALACTOSE MOIETY OF SUBSTRATE GLYCOPROTEIN.
RX   PubMed=18400750; DOI=10.1074/jbc.M709556200;
RA   Tone Y., Pedersen L.C., Yamamoto T., Izumikawa T., Kitagawa H.,
RA   Nishihara J., Tamura J., Negishi M., Sugahara K.;
RT   "2-o-phosphorylation of xylose and 6-O-sulfation of galactose in the
RT   protein linkage region of glycosaminoglycans influence the
RT   glucuronyltransferase-I activity involved in the linkage region
RT   synthesis.";
RL   J. Biol. Chem. 283:16801-16807(2008).
RN   [15]
RP   VARIANT JDSCD GLN-277.
RX   PubMed=24668659; DOI=10.1002/ajmg.a.36487;
RA   von Oettingen J.E., Tan W.H., Dauber A.;
RT   "Skeletal dysplasia, global developmental delay, and multiple
RT   congenital anomalies in a 5-year-old boy-report of the second family
RT   with B3GAT3 mutation and expansion of the phenotype.";
RL   Am. J. Med. Genet. A 164A:1580-1586(2014).
RN   [16]
RP   VARIANT JDSCD SER-223.
RX   PubMed=26086840; DOI=10.1002/ajmg.a.37209;
RA   Jones K.L., Schwarze U., Adam M.P., Byers P.H., Mefford H.C.;
RT   "A homozygous B3GAT3 mutation causes a severe syndrome with multiple
RT   fractures, expanding the phenotype of linkeropathy syndromes.";
RL   Am. J. Med. Genet. A 167A:2691-2696(2015).
RN   [17]
RP   VARIANT JDSCD LEU-140, CHARACTERIZATION OF VARIANT JDSCD LEU-140,
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=25893793; DOI=10.1007/s00439-015-1549-2;
RA   Budde B.S., Mizumoto S., Kogawa R., Becker C., Altmueller J.,
RA   Thiele H., Rueschendorf F., Toliat M.R., Kaleschke G., Haemmerle J.M.,
RA   Hoehne W., Sugahara K., Nuernberg P., Kennerknecht I.;
RT   "Skeletal dysplasia in a consanguineous clan from the island of
RT   Nias/Indonesia is caused by a novel mutation in B3GAT3.";
RL   Hum. Genet. 134:691-704(2015).
CC   -!- FUNCTION: Glycosaminoglycans biosynthesis (PubMed:25893793).
CC       Involved in forming the linkage tetrasaccharide present in heparan
CC       sulfate and chondroitin sulfate. Transfers a glucuronic acid
CC       moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to
CC       the common linkage region trisaccharide Gal-beta-1,3-Gal-beta-1,4-
CC       Xyl covalently bound to a Ser residue at the glycosaminylglycan
CC       attachment site of proteoglycans. Can also play a role in the
CC       biosynthesis of l2/HNK-1 carbohydrate epitope on glycoproteins.
CC       Shows strict specificity for Gal-beta-1,3-Gal-beta-1,4-Xyl,
CC       exhibiting negligible incorporation into other galactoside
CC       substrates including Galbeta1-3Gal beta1-O-benzyl, Galbeta1-
CC       4GlcNAc and Galbeta1-4Glc. Stimulates 2-phosphoxylose phosphatase
CC       activity of PXYLP1 in presence of uridine diphosphate-glucuronic
CC       acid (UDP-GlcUA) during completion of linkage region formation
CC       (PubMed:24425863). {ECO:0000269|PubMed:24425863,
CC       ECO:0000269|PubMed:25893793}.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-glucuronate + [protein]-3-O-(beta-
CC       D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-xylosyl)-L-
CC       serine = UDP + [protein]-3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-
CC       (1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-serine.
CC       {ECO:0000269|PubMed:25893793}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC   -!- ENZYME REGULATION: Inhibited by EDTA.
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. Interacts with PXYLP1; the
CC       interaction increases the 2-phosphoxylose phosphatase activity of
CC       PXYLP1 during completion of linkage region formation in a B3GAT3-
CC       mediated manner. {ECO:0000269|PubMed:10946001,
CC       ECO:0000269|PubMed:11950836, ECO:0000269|PubMed:18400750,
CC       ECO:0000269|PubMed:24425863}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:21763480}; Single-pass type II membrane
CC       protein {ECO:0000269|PubMed:21763480}. Golgi apparatus, cis-Golgi
CC       network {ECO:0000269|PubMed:21763480,
CC       ECO:0000269|PubMed:25893793}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O94766-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O94766-2; Sequence=VSP_056347;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous (but weakly expressed in all
CC       tissues examined).
CC   -!- PTM: N-glycosylated.
CC   -!- DISEASE: Multiple joint dislocations, short stature, and
CC       craniofacial dysmorphism with or without congenital heart defects
CC       (JDSCD) [MIM:245600]: An autosomal recessive disease characterized
CC       by dysmorphic facies, bilateral dislocations of the elbows, hips,
CC       and knees, clubfeet, and short stature, as well as cardiovascular
CC       defects. {ECO:0000269|PubMed:21763480,
CC       ECO:0000269|PubMed:24668659, ECO:0000269|PubMed:25893793,
CC       ECO:0000269|PubMed:26086840}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 43 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB009598; BAA34537.1; -; mRNA.
DR   EMBL; AK316228; BAH14599.1; -; mRNA.
DR   EMBL; AP001458; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007906; AAH07906.1; -; mRNA.
DR   EMBL; BC071961; AAH71961.1; -; mRNA.
DR   EMBL; AJ005865; CAA06742.1; -; mRNA.
DR   CCDS; CCDS76418.1; -. [O94766-2]
DR   CCDS; CCDS8025.1; -. [O94766-1]
DR   RefSeq; NP_001275652.1; NM_001288723.1. [O94766-2]
DR   RefSeq; NP_036332.2; NM_012200.3. [O94766-1]
DR   UniGene; Hs.502759; -.
DR   PDB; 1FGG; X-ray; 2.30 A; A/B=76-335.
DR   PDB; 1KWS; X-ray; 2.10 A; A/B=76-335.
DR   PDB; 3CU0; X-ray; 1.90 A; A/B=76-335.
DR   PDBsum; 1FGG; -.
DR   PDBsum; 1KWS; -.
DR   PDBsum; 3CU0; -.
DR   ProteinModelPortal; O94766; -.
DR   SMR; O94766; -.
DR   BioGrid; 117620; 24.
DR   IntAct; O94766; 1.
DR   STRING; 9606.ENSP00000265471; -.
DR   DrugBank; DB03041; UDP-alpha-D-glucuronic acid.
DR   DrugBank; DB03435; Uridine-5'-Diphosphate.
DR   CAZy; GT43; Glycosyltransferase Family 43.
DR   iPTMnet; O94766; -.
DR   BioMuta; B3GAT3; -.
DR   EPD; O94766; -.
DR   MaxQB; O94766; -.
DR   PaxDb; O94766; -.
DR   PeptideAtlas; O94766; -.
DR   PRIDE; O94766; -.
DR   DNASU; 26229; -.
DR   Ensembl; ENST00000265471; ENSP00000265471; ENSG00000149541. [O94766-1]
DR   Ensembl; ENST00000534026; ENSP00000432474; ENSG00000149541. [O94766-2]
DR   GeneID; 26229; -.
DR   KEGG; hsa:26229; -.
DR   UCSC; uc001ntw.3; human. [O94766-1]
DR   CTD; 26229; -.
DR   DisGeNET; 26229; -.
DR   GeneCards; B3GAT3; -.
DR   HGNC; HGNC:923; B3GAT3.
DR   HPA; HPA051328; -.
DR   MalaCards; B3GAT3; -.
DR   MIM; 245600; phenotype.
DR   MIM; 606374; gene.
DR   neXtProt; NX_O94766; -.
DR   OpenTargets; ENSG00000149541; -.
DR   Orphanet; 284139; Larsen-like syndrome, B3GAT3 type.
DR   PharmGKB; PA25217; -.
DR   eggNOG; KOG1476; Eukaryota.
DR   eggNOG; ENOG410XP79; LUCA.
DR   GeneTree; ENSGT00390000017640; -.
DR   HOVERGEN; HBG050650; -.
DR   InParanoid; O94766; -.
DR   KO; K10158; -.
DR   OMA; KEMRWTR; -.
DR   OrthoDB; EOG091G0G8P; -.
DR   PhylomeDB; O94766; -.
DR   TreeFam; TF313522; -.
DR   BioCyc; MetaCyc:HS07624-MONOMER; -.
DR   BRENDA; 2.4.1.135; 2681.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   SABIO-RK; O94766; -.
DR   UniPathway; UPA00378; -.
DR   ChiTaRS; B3GAT3; human.
DR   EvolutionaryTrace; O94766; -.
DR   GeneWiki; B3GAT3; -.
DR   GenomeRNAi; 26229; -.
DR   PRO; PR:O94766; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000149541; -.
DR   CleanEx; HS_B3GAT3; -.
DR   ExpressionAtlas; O94766; baseline and differential.
DR   Genevisible; O94766; HS.
DR   GO; GO:0005801; C:cis-Golgi network; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0015018; F:galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity; IBA:GO_Central.
DR   GO; GO:0015020; F:glucuronosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0072542; F:protein phosphatase activator activity; IDA:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IBA:GO_Central.
DR   GO; GO:0030204; P:chondroitin sulfate metabolic process; IBA:GO_Central.
DR   GO; GO:0050650; P:chondroitin sulfate proteoglycan biosynthetic process; IDA:MGI.
DR   GO; GO:0050651; P:dermatan sulfate proteoglycan biosynthetic process; IDA:MGI.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IDA:MGI.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IDA:UniProtKB.
DR   GO; GO:0090316; P:positive regulation of intracellular protein transport; IMP:UniProtKB.
DR   GO; GO:0006486; P:protein glycosylation; IEA:UniProtKB-UniPathway.
DR   CDD; cd00218; GlcAT-I; 1.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR005027; Glyco_trans_43.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   PANTHER; PTHR10896; PTHR10896; 1.
DR   Pfam; PF03360; Glyco_transf_43; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Golgi apparatus;
KW   Manganese; Membrane; Metal-binding; Reference proteome; Signal-anchor;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    335       Galactosylgalactosylxylosylprotein 3-
FT                                beta-glucuronosyltransferase 3.
FT                                /FTId=PRO_0000195176.
FT   TOPO_DOM      1      7       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM      8     28       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     29    335       Lumenal. {ECO:0000255}.
FT   NP_BIND      82     84       UDP-glucuronate binding.
FT   NP_BIND     194    196       UDP-glucuronate binding.
FT   NP_BIND     308    310       UDP-glucuronate binding.
FT   REGION      243    252       Interaction with galactose moiety of
FT                                substrate glycoprotein.
FT   ACT_SITE    281    281       Proton donor/acceptor.
FT                                {ECO:0000269|PubMed:11950836}.
FT   METAL       196    196       Manganese.
FT   BINDING     113    113       UDP-glucuronate.
FT   BINDING     156    156       UDP-glucuronate.
FT   BINDING     161    161       UDP-glucuronate.
FT   SITE        227    227       Interaction with galactose moiety of
FT                                substrate glycoprotein.
FT   SITE        318    318       Interaction with galactose moiety of
FT                                substrate glycoprotein.
FT   CARBOHYD    300    300       N-linked (GlcNAc...) asparagine.
FT   DISULFID     33     33       Interchain.
FT   VAR_SEQ     304    335       VLVWHTRTEKPKMKQEEQLQRQGRGSDPAIEV -> TESRC
FT                                VTQAGVQ (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056347.
FT   VARIANT     140    140       P -> L (in JDSCD; reduced
FT                                glucuronyltransferase activity; patient
FT                                fibroblasts have decreased levels of
FT                                dermatan sulfate, chondroitin sulfate and
FT                                heparan sulfate proteoglycans).
FT                                {ECO:0000269|PubMed:25893793}.
FT                                /FTId=VAR_075370.
FT   VARIANT     223    223       G -> S (in JDSCD; unknown pathological
FT                                significance; dbSNP:rs372487178).
FT                                {ECO:0000269|PubMed:26086840}.
FT                                /FTId=VAR_075371.
FT   VARIANT     277    277       R -> Q (in JDSCD; reduced
FT                                glucuronyltransferase activity; patient
FT                                fibroblasts have decreased levels of
FT                                dermatan sulfate, chondroitin sulfate and
FT                                heparan sulfate proteoglycans;
FT                                dbSNP:rs387906937).
FT                                {ECO:0000269|PubMed:21763480,
FT                                ECO:0000269|PubMed:24668659}.
FT                                /FTId=VAR_066624.
FT   MUTAGEN      33     33       C->A: Loss of dimer formation and reduced
FT                                activity. {ECO:0000269|PubMed:10842173}.
FT   MUTAGEN     281    281       E->A: Absence of enzymatic activity in
FT                                presence of uridine diphosphate-
FT                                glucuronic acid (UDP-GlcUA). Does not
FT                                increase PXYLP1-induced 2-phosphoxylose
FT                                phosphatase activity in presence of
FT                                uridine diphosphate-glucuronic acid (UDP-
FT                                GlcUA). {ECO:0000269|PubMed:24425863,
FT                                ECO:0000303|PubMed:24425863}.
FT   MUTAGEN     301    301       C->A: Enzyme inactivation and loss of
FT                                glycosylation.
FT                                {ECO:0000269|PubMed:10842173}.
FT   CONFLICT    204    204       F -> S (in Ref. 1; BAA34537).
FT                                {ECO:0000305}.
FT   STRAND       76     83       {ECO:0000244|PDB:3CU0}.
FT   HELIX        89    100       {ECO:0000244|PDB:3CU0}.
FT   STRAND      103    116       {ECO:0000244|PDB:3CU0}.
FT   HELIX       119    128       {ECO:0000244|PDB:3CU0}.
FT   STRAND      130    136       {ECO:0000244|PDB:3CU0}.
FT   HELIX       158    168       {ECO:0000244|PDB:3CU0}.
FT   STRAND      174    177       {ECO:0000244|PDB:3CU0}.
FT   STRAND      188    192       {ECO:0000244|PDB:3CU0}.
FT   STRAND      197    199       {ECO:0000244|PDB:3CU0}.
FT   HELIX       201    207       {ECO:0000244|PDB:3CU0}.
FT   STRAND      211    215       {ECO:0000244|PDB:3CU0}.
FT   STRAND      218    221       {ECO:0000244|PDB:3CU0}.
FT   STRAND      224    232       {ECO:0000244|PDB:3CU0}.
FT   STRAND      235    240       {ECO:0000244|PDB:3CU0}.
FT   HELIX       253    255       {ECO:0000244|PDB:3CU0}.
FT   STRAND      256    259       {ECO:0000244|PDB:3CU0}.
FT   HELIX       260    265       {ECO:0000244|PDB:3CU0}.
FT   HELIX       280    285       {ECO:0000244|PDB:3CU0}.
FT   TURN        286    288       {ECO:0000244|PDB:3CU0}.
FT   HELIX       291    293       {ECO:0000244|PDB:3CU0}.
FT   HELIX       298    301       {ECO:0000244|PDB:3CU0}.
FT   HELIX       317    323       {ECO:0000244|PDB:3CU0}.
FT   TURN        324    326       {ECO:0000244|PDB:3CU0}.
SQ   SEQUENCE   335 AA;  37122 MW;  5EC45408597F1C0F CRC64;
     MKLKLKNVFL AYFLVSIAGL LYALVQLGQP CDCLPPLRAA AEQLRQKDLR ISQLQAELRR
     PPPAPAQPPE PEALPTIYVV TPTYARLVQK AELVRLSQTL SLVPRLHWLL VEDAEGPTPL
     VSGLLAASGL LFTHLVVLTP KAQRLREGEP GWVHPRGVEQ RNKALDWLRG RGGAVGGEKD
     PPPPGTQGVV YFADDDNTYS RELFEEMRWT RGVSVWPVGL VGGLRFEGPQ VQDGRVVGFH
     TAWEPSRPFP VDMAGFAVAL PLLLDKPNAQ FDSTAPRGHL ESSLLSHLVD PKDLEPRAAN
     CTRVLVWHTR TEKPKMKQEE QLQRQGRGSD PAIEV
//
